Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum

July 7th 2025

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

FDA Approves Oncomine Dx Express Test for Tumor Profiling and as Companion Diagnostic for Sunvozertinib in NSCLC

July 7th 2025

The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Dr Spigel on a 14-Gene Assay for Clarifying the Benefit of Adjuvant Chemo in NSCLC

July 2nd 2025

David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.

Dr Bazhenova on the FDA Approval of Sunvozertinib for EGFR-Mutated mNSCLC

July 2nd 2025

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

July 2nd 2025

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy) for locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.

Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials

July 1st 2025

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer

June 30th 2025

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

China NMPA Approves Savolitinib Plus Osimertinib for EGFR-Mutant, MET-Amplified NSCLC

June 30th 2025

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.

2025 Giants of Cancer Care: OncLive® Honors 13 Cancer Care Pioneers

June 30th 2025

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

Five Under 5: Top Oncology Videos for the Week of 6/22

June 29th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

The OncFive: Top Oncology Articles for the Week of 6/22

June 28th 2025

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.

CheckMate 816 at ASCO 2025: OS Update and Impact on Early-Stage NSCLC Care

June 27th 2025

Panelists discuss how the CheckMate 816 overall survival data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated a significant survival benefit with neoadjuvant chemoimmunotherapy, particularly in patients with higher PD-L1 expression and those achieving pathologic complete responses (pCRs).

Resectable Early-Stage NSCLC: How the Standard of Care Is Evolving

June 27th 2025

Panelists discuss how the standard of care for resectable early-stage non–small cell lung cancer (NSCLC) has evolved from adjuvant chemotherapy alone to neoadjuvant chemoimmunotherapy and perioperative approaches that combine preoperative treatment with continued immunotherapy after surgery.

Frontline Firmonertinib Generates Durable Efficacy in EGFR PACC–Mutant NSCLC

June 26th 2025

Firmonertinib produced durable responses in the first line treatment of patients with non–small cell lung cancer harboring EGFR PACC mutations.

NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC

June 25th 2025

The NCCN Clinical Practice Guidelines in Oncology for NSCLC recommend taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC.

Dr Cameron on the Prognostic Value of PD-L1 for Outcomes With Osimertinib in EGFR+ NSCLC

June 24th 2025

Robert Cameron, MD, PhD, discusses a study examining the impact of PD-L1 expression on outcomes with osimertinib in EGFR-mutated NSCLC.

Serplulimab Earns UK Approval for First-Line ES-SCLC

June 24th 2025

Serplulimab is now the only anti–PD-1 monoclonal antibody approved by the MHRA for patients with extensive-stage small cell lung cancer in the first line.